Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2020

Details for Mechanism ID: 18213
Country/Region: Kenya
Year: 2017
Main Partner: Ministry of Health
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: HHS/CDC
Total Funding: $4,516,289 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $470,588
Laboratory Infrastructure (HLAB) $99,000
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $320,000
Biomedical Prevention: Injection Safety (HMIN) $50,000
Testing: HIV Testing and Counseling (HVCT) $300,000
Sexual Prevention: Other Sexual Prevention (HVOP) $582,353
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $300,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,514,706
Treatment: Adult Treatment (HTXS) $414,936
Treatment: Pediatric Treatment (PDTX) $464,706
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 21
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 226
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 52
GEND_GBV Number of people receiving post-GBV care 2018 278
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 11,942
HTS_TST Service Delivery Point Agg Age (Facility) ANC: <15, Negative 2018 6
HTS_TST Service Delivery Point Agg Age (Facility) ANC: 15+, Negative 2018 1,026
HTS_TST Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative 2018 213
HTS_TST Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative 2018 204
HTS_TST Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 5,654
HTS_TST Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 3,912
HTS_TST Sum of Test Result disaggregates 2018 518
HTS_TST_POS By Test Result: Positive 2018 518
HTS_TST_POS Service Delivery Point Agg Age (Facility) ANC: 15+, Positive 2018 108
HTS_TST_POS Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive 2018 8
HTS_TST_POS Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive 2018 32
HTS_TST_POS Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 244
HTS_TST_POS Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 535
PMTCT_ART Already on ART at beginning of current pregnancy 2018 67
PMTCT_ART New on ART 2018 34
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 101
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 1,140
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 101
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 21
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 78
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 1
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 1
PMTCT_STAT By Age (Numerator): : 15-19 2018 123
PMTCT_STAT By Age (Numerator): 10-14 2018 5
PMTCT_STAT By Age (Numerator): 20-24 2018 377
PMTCT_STAT By Age (Numerator): 25-49 2018 635
PMTCT_STAT By known positives: 15-19 2018 42
PMTCT_STAT By known positives: 20-24 2018 17
PMTCT_STAT By known positives: 25-49 2018 40
PMTCT_STAT By new negatives: 10-14 2018 5
PMTCT_STAT By new negatives: 15-19 2018 87
PMTCT_STAT By new negatives: 20-24 2018 358
PMTCT_STAT By new negatives: 25-49 2018 580
PMTCT_STAT By new positives: 15-19 2018 1
PMTCT_STAT By new positives: 20-24 2018 2
PMTCT_STAT By new positives: 25-49 2018 7
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 1,140
PMTCT_STAT_den By Age (Denominator): 10-14 2018 5
PMTCT_STAT_den By Age (Denominator): 15-19 2018 123
PMTCT_STAT_den By Age (Denominator): 20-24 2018 377
PMTCT_STAT_den By Age (Denominator): 25-49 2018 635
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 2
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 66
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 1
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 3
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 72
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 36
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 143
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 1
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 17
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 1
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 18
TB_PREV By Age/Sex (Numerator): <15, Female 2018 4
TB_PREV By Age/Sex (Numerator): <15, Male 2018 3
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 61
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 29
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 318
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 353
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 4
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 4
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 68
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 32
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 27
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 398
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 41
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 549
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 1,015
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 1,360
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 39
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 532
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 53
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 736
TX_CURR Aggregated Age/Sex: <15 Female 2018 61
TX_CURR Aggregated Age/Sex: <15 Male 2018 56
TX_CURR Aggregated Age/Sex: 15+ Female 2018 835
TX_CURR Aggregated Age/Sex: 15+ Male 2018 390
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 1,342
TX_CURR Sum of Aggregated Age/Sex <15 2018 117
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 1,225
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 1,342
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 5
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 3
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 233
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 111
TX_NEW Breastfeeding status 2018 2
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 353
TX_NEW Pregnancy status 2018 17
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 352
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 1,328
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 1,187
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 41
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 4
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 37
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 2
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 705
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 52
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 320
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 26
TX_PVLS Numerator: Indication: Routine 2018 1,103
TX_PVLS Numerator: Indication: Targeted 2018 84
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Routine 2018 20
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Targeted 2018 4
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 10
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Targeted 2018 2
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 49
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 4
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 45
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 3
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 785
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 60
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 355
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 27
TX_PVLS_den Denominator: Indication: Routine 2018 1,234
TX_PVLS_den Denominator: Indication: Targeted 2018 94
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Routine 2018 23
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Targeted 2018 5
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 11
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Targeted 2018 2
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 7
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 3
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 222
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 104
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 336
TX_RET Numerator by Status: Breastfeeding 2018 10
TX_RET Numerator by Status: Pregnant 2018 17
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 336
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 7
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 222
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 104
TX_RET_den Denominator by Status: Breastfeeding 2018 10
TX_RET_den Denominator by Status: Pregnant 2018 17
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 56
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 1
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 58
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 1
Cross Cutting Budget Categories and Known Amounts Total: $1,570,000
Gender: Gender Equality $50,000
Promoting gender-related policies and laws that increase legal protection
Key Populations: MSM and TG $100,000
Training of health workers and community outreach workers
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $120,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Gender: Gender Based Violence (GBV) $50,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $50,000
Promoting gender-related policies and laws that increase legal protection
Human Resources for Health $1,200,000